The science behind supplements for female fertility Folate ubiquinol probiotics and emerging approaches to reproductive health support

Nutritional interventions in female reproductive health occupy different positions along the continuum fromestablished prevention to experimental adjunctive treatment. Folic acid has a strong evidence base forreducing neural tube defects when used periconceptionally; this indication must be distinguished fromtreatment of infertility. Folate metabolism also provides substrates for nucleotide synthesis and methylation,but biochemical plausibility and observational associations with assisted reproduction do not establish thathigher doses or methylfolate formulations increase live birth. Coenzyme Q10 links mitochondrial electrontransport with redox homeostasis and has produced encouraging findings in selected populations withdiminished ovarian reserve or poor ovarian response. Nevertheless, clinical studies differ in eligibility,formulation, cointerventions and analytical denominators. Recent syntheses include favorable live birthsignals, while uncertainty remains over reproducibility, applicability and the reproductive superiority ofubiquinol over ubiquinone. Probiotics and synbiotics introduce a further layer of specificity because strainidentity, delivery route, ecological context and formulation influence activity. Emerging trials and a 2026meta-analysis support continued investigation, but microbiome modification, prevention of recurrentbacterial vaginosis and improved reproductive outcomes are separate claims.This critical narrative review integrates biochemical mechanisms, selected human trials, contemporaryevidence syntheses and professional guidance available through September 9, 2026. It examines folate formsand MTHFR interpretation, CoQ10 pharmacokinetics and ovarian endpoints, vaginal and endometrialmicrobiome research, and developments in metabolic and nutritional personalization. Comparative evidencetables distinguish established preventive use from promising but incompletely validated fertilityapplications. The central translational requirement is alignment between the studied population, the finishedformulation and a clinically meaningful endpoint. Future development should prioritize cumulative live birth,time to pregnancy, maternal and neonatal safety, and transparent evaluation of the final product rather thanassuming that ingredient-level mechanisms establish combination efficacy.